IBDEI1FQ ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.4)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.4,928,0)
 ;;=NURSING VISIT ONLY^1^94
 ;;^UTILITY(U,$J,358.4,929,0)
 ;;=INITIAL OBSERVATION^9^94
 ;;^UTILITY(U,$J,358.4,930,0)
 ;;=SAME DAY ADM/DISCHARGE^12^94
 ;;^UTILITY(U,$J,358.4,931,0)
 ;;=INPT CONSULTATIONS^5^94
 ;;^UTILITY(U,$J,358.4,932,0)
 ;;=INITIAL HOSPITAL CARE^6^94
 ;;^UTILITY(U,$J,358.4,933,0)
 ;;=SUBSEQUENT HOSPITAL CARE^7^94
 ;;^UTILITY(U,$J,358.4,934,0)
 ;;=HOSPITAL CARE D/C SERVICES^8^94
 ;;^UTILITY(U,$J,358.4,935,0)
 ;;=SUBSEQUENT OBSERVATION CARE^10^94
 ;;^UTILITY(U,$J,358.4,936,0)
 ;;=OBSERVATION CARE D/C SERVICES^11^94
 ;;^UTILITY(U,$J,358.4,937,0)
 ;;=DIALYSIS ENCOUNTER^1^95
 ;;^UTILITY(U,$J,358.4,938,0)
 ;;=PERITONEAL DIALYSIS ENCOUNTER^2^95
 ;;^UTILITY(U,$J,358.4,939,0)
 ;;=CARDIOLOGY^3^95
 ;;^UTILITY(U,$J,358.4,940,0)
 ;;=COMPLICATIONS/OTHER^4^95
 ;;^UTILITY(U,$J,358.4,941,0)
 ;;=CYSTIC KIDNEY DISEASE^5^95
 ;;^UTILITY(U,$J,358.4,942,0)
 ;;=DIABETES/DIABETIC RENAL DISEASE^6^95
 ;;^UTILITY(U,$J,358.4,943,0)
 ;;=FLUID/ELECTROLYTES DISORDER^7^95
 ;;^UTILITY(U,$J,358.4,944,0)
 ;;=GENERAL SYMPTOMS^8^95
 ;;^UTILITY(U,$J,358.4,945,0)
 ;;=GENITAL/URINARY^9^95
 ;;^UTILITY(U,$J,358.4,946,0)
 ;;=HEMATOLOGY^10^95
 ;;^UTILITY(U,$J,358.4,947,0)
 ;;=HYPERTENSION PRIMARY^11^95
 ;;^UTILITY(U,$J,358.4,948,0)
 ;;=HYPERTENSION SECONDAY^12^95
 ;;^UTILITY(U,$J,358.4,949,0)
 ;;=HYPERTENSIVE HEART/RENAL^13^95
 ;;^UTILITY(U,$J,358.4,950,0)
 ;;=INFECTIOUS DISEASE^14^95
 ;;^UTILITY(U,$J,358.4,951,0)
 ;;=NEPHRITIS GLOMERULONEPHRITIS^15^95
 ;;^UTILITY(U,$J,358.4,952,0)
 ;;=NEPHRITIS INTERSTITIAL^16^95
 ;;^UTILITY(U,$J,358.4,953,0)
 ;;=NEPHROTIC SYNDROME^17^95
 ;;^UTILITY(U,$J,358.4,954,0)
 ;;=OBSTRUCTIVE UROPATHY/STONES^18^95
 ;;^UTILITY(U,$J,358.4,955,0)
 ;;=ONCOLOGY^19^95
 ;;^UTILITY(U,$J,358.4,956,0)
 ;;=TRANSPLANTATION^21^95
 ;;^UTILITY(U,$J,358.4,957,0)
 ;;=PROLONGED SERVICES^1^96
 ;;^UTILITY(U,$J,358.4,958,0)
 ;;=ESTABLISHED PATIENT^1^97
 ;;^UTILITY(U,$J,358.4,959,0)
 ;;=CONSULTATIONS/OPINIONS^2^97
 ;;^UTILITY(U,$J,358.4,960,0)
 ;;=NEWPATIENTS^3^97
 ;;^UTILITY(U,$J,358.4,961,0)
 ;;=CEREBROVASCULAR DIS^2^98
 ;;^UTILITY(U,$J,358.4,962,0)
 ;;=SEIZURES/EPILEPSY/SPELLS^5^98
 ;;^UTILITY(U,$J,358.4,963,0)
 ;;=HEADACHE^6^98
 ;;^UTILITY(U,$J,358.4,964,0)
 ;;=DIZZINESS^3^98
 ;;^UTILITY(U,$J,358.4,965,0)
 ;;=NEURODEGENERATIVE DIS^9^98
 ;;^UTILITY(U,$J,358.4,966,0)
 ;;=PAIN^12^98
 ;;^UTILITY(U,$J,358.4,967,0)
 ;;=NEUROPATHIES^10^98
 ;;^UTILITY(U,$J,358.4,968,0)
 ;;=ENCEPALOPATHY^4^98
 ;;^UTILITY(U,$J,358.4,969,0)
 ;;=SPINAL CONDITIONS^14^98
 ;;^UTILITY(U,$J,358.4,970,0)
 ;;=VISION DISTURBANCES^16^98
 ;;^UTILITY(U,$J,358.4,971,0)
 ;;=MOVEMENT DISORDERS^15^98
 ;;^UTILITY(U,$J,358.4,972,0)
 ;;=OTHER^13^98
 ;;^UTILITY(U,$J,358.4,973,0)
 ;;=CARDIAC DISORDERS^1^98
 ;;^UTILITY(U,$J,358.4,974,0)
 ;;=NEOPLASMS^8^98
 ;;^UTILITY(U,$J,358.4,975,0)
 ;;=SYMPTOMS^17^98
 ;;^UTILITY(U,$J,358.4,976,0)
 ;;=NEUROLOGY/SEIZURE^6^99
 ;;^UTILITY(U,$J,358.4,977,0)
 ;;=EEG^3^99
 ;;^UTILITY(U,$J,358.4,978,0)
 ;;=SLEEP TESTING^7^99
 ;;^UTILITY(U,$J,358.4,979,0)
 ;;=MUSCLE TESTING/EMG^5^99
 ;;^UTILITY(U,$J,358.4,980,0)
 ;;=EVOKED POTENTIAL^4^99
 ;;^UTILITY(U,$J,358.4,981,0)
 ;;=BIOPSY^2^99
 ;;^UTILITY(U,$J,358.4,982,0)
 ;;=AUTONOMIC FUNCTION TESTS^1^99
 ;;^UTILITY(U,$J,358.4,983,0)
 ;;=STEREOTACTIC^8^99
 ;;^UTILITY(U,$J,358.4,984,0)
 ;;=CERVICAL^1^100
 ;;^UTILITY(U,$J,358.4,985,0)
 ;;=EXTREMITIES/MISC.^3^100
 ;;^UTILITY(U,$J,358.4,986,0)
 ;;=HEAD/CEREBRAL^4^100
 ;;^UTILITY(U,$J,358.4,987,0)
 ;;=SPINAL CORD/COLUMN^8^100
 ;;^UTILITY(U,$J,358.4,988,0)
 ;;=COMP PROC/MED CARE^2^100
 ;;^UTILITY(U,$J,358.4,989,0)
 ;;=SIGNS AND SYMPTOMS^7^100
